A VC’s take on the $1.3 billion acquisition of CinCor Pharma by AstraZeneca
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.